-
Trading Resumes: Columbia Laboratories (CBRX)
Wednesday, April 6, 2011 - 11:20am | 14Trading Resumes: Columbia Laboratories (NASDAQ: CBRX)
-
Calls Purchased on Watson Pharmaceuticals (WPI)
Wednesday, April 6, 2011 - 10:40am | 130Shares of Watson Pharmaceuticals (NYSE: WPI) are higher on the session by 1.07%, currently trading at $58.46. The stock has been moving largely higher over the past six months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying calls on the name today...
-
Stocks Going Ex Dividend the Second Week of April
Wednesday, April 6, 2011 - 9:59am | 742Here is our latest update on the stock trading technique called 'Buying Dividends'. This is the process of buying stocks before the ex dividend date and selling the stock shortly after the ex date at about the same price, yet still being entitled to the dividend. This technique generally works only...
-
Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share
Wednesday, April 6, 2011 - 9:54am | 25Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share..
-
Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share
Wednesday, April 6, 2011 - 9:54am | 25Unconfirmed Rumors Circulate that (GSK) will acquire (IMMU) at 10.00 a share..
-
Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE Vaginal Progesterone Gel Study Results
Wednesday, April 6, 2011 - 9:44am | 167Columbia Laboratories, Inc. (Nasdaq: CBRX), and Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced the publication of Phase III PROCHIEVE data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound...
-
Teva and OncoGenex Present Preclinical Data on the Activity of its Antisense Compound Custirsen at the American Association of Cancer Research Annual Meeting
Wednesday, April 6, 2011 - 9:27am | 189Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that new preclinical data of their investigational compound custirsen in castrate resistant prostate cancer were presented this week at the 102nd Annual Meeting of the AACR. These...
-
Oppenheimer Raises OPTR Price Target to $17
Wednesday, April 6, 2011 - 9:05am | 92Oppenheimer has issued a report raising the Price Target on Optimer Pharmaceuticals (NASDAQ: OPTR) from $14 to $17 following the FDA safety approval of fidaxomicin. According to the report, "We continue to anticipate approval of fidaxomicin by the May 30th PDUFA based on the panel's unanimous vote...
-
Columbia Laboratories Halted (CBRX)
Wednesday, April 6, 2011 - 8:49am | 13Columbia Laboratories Halted (NASDAQ: CBRX)
-
UPDATE; Deutsche Bank Raises PT on Inspire Pharmaceuticals to $5 (ISPH)
Wednesday, April 6, 2011 - 8:38am | 106Deutsche Bank is out with its report today on Inspire Pharmaceuticals (NASDAQ: ISPH), raising its PT from $4 to $5, after Merck announced its agreement to acquire Inspire Pharmaceuticals. In a note to clients, Deutsche Bank writes, "Merck's proposed valuation is in line with our sum-of-the-parts...
-
Benzinga's Top Pre-Market NASDAQ Losers (AMSC, OPTR, CIEN, GOLD)
Wednesday, April 6, 2011 - 8:16am | 130American Superconductor Corporation (NASDAQ: AMSC) dipped 43.33% to $14.10 in the pre-market session. AMSC projects a loss and lower revenue for its fiscal fourth quarter and forecast lower-than-expected earnings for the full year. Optimer Pharmaceuticals Inc (NASDAQ: OPTR) lost 2.17% to $13.50 in...
-
Jefferies Has Buy Rating On Optimer Pharm. (OPTR)
Wednesday, April 6, 2011 - 7:48am | 97Jefferies & Co. has a Buy rating and a $17 price target on shares of Optimer Pharm. (NASDAQ: OPTR). In a note to clients, Jefferies writes, "As expected, DIFICID (fidaxomicin) gets a positive FDA panel vote for treatment of CDAD (13-0), but the panel votes were mixed on reducing risk of...
-
Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID for Clostridium difficile Infection in the United States
Wednesday, April 6, 2011 - 7:28am | 141Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID (fidaxomicin), in the United States. DIFICID is a novel antibiotic currently being reviewed for market...
-
Oppenheimer Raises PT On Optimer Pharmaceuticals To $17
Wednesday, April 6, 2011 - 7:21am | 26Oppenheimer has raised the price target on Optimer Pharmaceuticals (NASDAQ: OPTR) from $14 to $17 and maintains its Outperform rating.
-
US Stock Futures Up As Investors Await Monsanto Earnings, Gold Futures Hit New High, American Superconductor Shares Drop In Pre-Market Trading
Wednesday, April 6, 2011 - 6:20am | 472US stock futures are higher this morning, as investors are awaiting quarterly results from Monsanto Co (NYSE: MON). Gold futures surged to a new high. Futures for the Dow Jones Industrial Average surged 44 points to 12,371.00, while those for the S&P 500 index rose 5.40 points to 1,332.10....